Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery

NCT03819010 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03819010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03819010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
May 7, 2019
Completion date
December 31, 2019
Enrollment
66 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer